Unichem Lab receives ANDA approval for Divalproex Sodium ER tablets

6 Mar 2022 , 01:33 AM

Unichem Laboratories has received ANDA approval for its Divalproex Sodium Extended-Release Tablets USP 250 mg and 500 mg from the United States Food and Drug Administration USFDA to market a generic version of Depakote ER Divalproex Sodium Extended-Release Tablets 250 mg and 500 mg of AbbVie Inc Divalproex Sodium Extended-Release Tablets are indicated for treatment of acute manic or mixed episodes associated with bipolar disorder as monotherapy and adjunctive therapy and prophylaxis of migraine headaches The product will be commercialized from Unichems Goa Plant